| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
4.53(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
773,595 |
| 52
Week Range: |
$23.37 - $33.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 581 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
35,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
15,666 |
15,666 |
89,488 |
206,962 |
| Total Sell Value |
$454,291 |
$454,291 |
$2,700,159 |
$6,056,962 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
3 |
3 |
7 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Snyderman Nancy Lynn Md |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
22,213 |
|
- |
|
| Cooke Shane |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$92,568 |
D/D |
(3,098) |
96,977 |
|
- |
|
| Cooke Shane |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
100,075 |
|
- |
|
| Alva Emily Peterson |
Director |
• • – |
2023-06-09 |
4 |
D |
$31.13 |
$28,359 |
D/D |
(911) |
15,195 |
|
- |
|
| Alva Emily Peterson |
Director |
• • – |
2023-06-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,795 |
16,106 |
|
- |
|
| Wright Christopher I |
Director |
• • – |
2023-06-08 |
4 |
D |
$31.54 |
$27,345 |
D/D |
(867) |
2,742 |
|
- |
|
| Wright Christopher I |
Director |
• • – |
2023-06-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,609 |
3,519 |
|
- |
|
| Laurencin Cato T |
Director |
• • – |
2023-06-08 |
4 |
AS |
$31.85 |
$84,020 |
D/D |
(2,638) |
7,479 |
|
-12% |
|
| Laurencin Cato T |
Director |
• • – |
2023-06-08 |
4 |
OE |
$22.97 |
$60,595 |
D/D |
2,638 |
10,117 |
|
- |
|
| Laurencin Cato T |
Director |
• • – |
2023-06-07 |
4 |
AS |
$31.50 |
$88,200 |
D/D |
(2,800) |
7,479 |
|
-10% |
|
| Laurencin Cato T |
Director |
• • – |
2023-06-07 |
4 |
OE |
$22.97 |
$64,316 |
D/D |
2,800 |
10,279 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2023-06-05 |
4 |
D |
$29.46 |
$45,810 |
D/D |
(1,555) |
42,929 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2023-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
44,484 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2023-05-30 |
4 |
AS |
$28.93 |
$784,862 |
D/D |
(27,134) |
40,984 |
|
-2% |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2023-05-30 |
4 |
OE |
$20.43 |
$401,123 |
D/D |
19,634 |
68,118 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2023-05-09 |
4 |
AS |
$31.24 |
$1,288,786 |
D/D |
(41,250) |
15,829 |
|
-3% |
|
| Wysenski Nancy |
Director |
• • – |
2023-05-09 |
4 |
OE |
$31.13 |
$1,284,113 |
D/D |
41,250 |
57,079 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2023-02-22 |
4 |
D |
$27.77 |
$75,090 |
D/D |
(2,704) |
48,484 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2023-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,969 |
51,188 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2023-02-22 |
4 |
D |
$27.77 |
$89,530 |
D/D |
(3,224) |
126,853 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2023-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,286 |
130,077 |
|
- |
|
| Jackson Blair Curtis |
EVP, Chief Operating Officer |
• • – |
2023-02-22 |
4 |
D |
$27.77 |
$85,754 |
D/D |
(3,088) |
114,117 |
|
- |
|
| Jackson Blair Curtis |
EVP, Chief Operating Officer |
• • – |
2023-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,504 |
117,205 |
|
- |
|
| Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
• • – |
2023-02-22 |
4 |
D |
$27.77 |
$68,370 |
D/D |
(2,462) |
250,442 |
|
- |
|
| Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
• • – |
2023-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,544 |
252,904 |
|
- |
|
2018 Records found
|
|
Page 5 of 81 |
|
|
0.24 (0.98%) 
